
~~WHAT IS CLAIMED IS:~~

1. A compound according to Formula Ia:



Ia

,

wherein

L_1 is a single bond, or CR^aR^b;

L_2 is a single bond, O, NR^e or CR^cR^d;

each of R^a, R^b, R^c, and R^d is independently selected from H, and C_{1-4} alkyl; or

R^a and R^b together with the carbon to which they are attached may form a C_{3-7} cycloalkyl; or

R^c and R^d together with the carbon to which they are attached may form a C_{3-7} cycloalkyl;

R^e is C_{1-4} alkyl;

Y is

- C_{1-4} alkyl optionally substituted with one or more groups independently selected from fluoro, OH, and phenyl (optionally substituted with one or more groups independently selected from C_{1-4} alkyl (optionally substituted with one or more halo), C_{1-4} alkoxy, halo and cyano), or
- C_{1-4} alkenyl comprising 1 double bond;

each of Cy_1 and Cy_2 is independently C_{6-10} aryl, or 5-10 membered heteroaryl;

each R^1 is independently selected from halo, C_{1-4} alkyl (optionally substituted with one or more halo), and C_{1-4} alkoxy (optionally substituted with one or more halo);

R^2 is:

- H,
- C_{1-4} alkyl optionally substituted with one or more independently selected R^{2a} groups,
- C_{3-7} cycloalkyl optionally substituted with one or more independently selected R^{2a} groups,

R^{2a} is

- halo,
- C_{1-6} alkoxy,
- OH,
- $C(=O)R^4$,
- $S(O)_2R^4$,
- CN,
- $NHC(=O)R^5$,
- $NHSO_2R^5$,
- 5-7 membered heterocycloalkyl (optionally substituted with one or more groups independently selected from C_{1-4} alkyl, and oxo), or

- 5-6 membered heteroaryl (optionally substituted with one or more groups independently selected from halo, OH, C_{1-4} alkoxy and C_{1-4} alkyl);

R^3 is selected from halo, C_{1-6} alkyl (optionally substituted with one or more halo), C_{1-6} alkoxy (optionally substituted with one or more halo, or phenyl), C_{1-6} thioalkoxy, phenyl (optionally substituted with one or more groups independently selected from halo, C_{1-4} alkyl (optionally substituted with one or more halo), C_{1-4} alkoxy, C(=O)-C_{1-4} alkoxy and CN);

R^4 is

- -OH,
- -C_{1-6} alkoxy,
- -*N*-linked 5-7 membered heterocycloalkyl (optionally substituted with one or more groups independently selected from C_{1-6} alkyl, and oxo),
- -$NR^{4a}R^{4b}$, or
- -$NHSO_2R^{4c}$;

Each of R^{4a} and R^{4b} is independently H, C_{1-4} alkyl (optionally substituted with phenyl (optionally substituted with one or more groups independently selected from halo, CN, C_{1-6} alkyl, and C_{1-6} alkoxy)), or C_{3-7} cycloalkyl;


R^{4c} is phenyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl (optionally substituted with one or more C_{1-4} alkyl) or C_{1-4} alkyl (optionally substituted with one or more halo);

R^5 is C_{1-4} alkyl (optionally substituted with one or more halo) or phenyl; and

the subscripts n and m are independently selected from 0, 1, and 2;

or a pharmaceutically acceptable salt, or a solvate, or a solvate of the pharmaceutically acceptable salts.

2. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is according to Formula Ib:




Ib


wherein L_1, L_2, R^1, R^2, R^3, Cy^1, Cy^2, R^a, R^b, R^c, R^d, R^e, Y, n, and m are as described in claim 1.

3. A compound or pharmaceutically acceptable salt thereof according to claims 1or 2, wherein Y is Me, Et, Pr, iPr, or $-CH_2-$Ph.

4. A compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein the compound is according to Formulae IIIa or IIIb:



IIIa



IIIb

wherein R^2, L_2, Cy_2, R^3 and m are as described in claim 1.

5. A compound or pharmaceutically acceptable salt thereof according to claims 1-4, wherein R^2 is $-(CH_2)$-COOH, $-(CH_2)_3$-COOH, $-(CH_2)_3$-SO_2NH_2, or $-(CH_2)_3$-SO_2NHMe.

6. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein Cy_2 is phenyl, or naphthalene.

7. A compound or pharmaceutically acceptable salt thereof, according to claim 1-5, wherein Cy_2 is thiophenyl, benzothiophenyl, benzofuranyl, benzoisoxazolyl, benzoxazolyl or indolyl.

8. A compound or pharmaceutically acceptable salt thereof according to any one of claim 1-7, wherein m is 1 or 2.

9. A compound or pharmaceutically acceptable salt thereof according to claim 8, wherein each R^3 group is independently selected from F, Cl, Br, Me, CF_3, and OMe.

10. A compound or pharmaceutically acceptable salt thereof according to any one of claim 1-7, wherein m is 0.

11. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-10, wherein L_2 is a single bond.

12. A compound or pharmaceutically acceptable salt thereof according to claim 1-10, wherein L_2 is $-CH_2$-.

13. A compound according to claim 1, wherein the compound is 4-[[(R)-1-(Benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-(3-chloro-benzyl)-amino]-butyric acid; or a pharmaceutically acceptable salt, or a solvate, or a solvate of the pharmaceutically acceptable salt.

14. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof, according to any of claims 1-13, and a pharmaceutically acceptable carrier.


15. The pharmaceutical composition according to claim 14 comprising a further therapeutic agent.

16. A compound, or pharmaceutically acceptable salt thereof, according to any of claims 1-15 for use as a medicament.

17. The compound, or pharmaceutically acceptable salt thereof, according to any one of claims 1-13, or the pharmaceutical composition according to claims 14 or 15, for use in the treatment or prophylaxis of inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

WHAT IS CLAIMED IS:

1. A compound according to Formula Ia:



Ia

,

wherein

L_1 is a single bond, or CR^aR^b;

L_2 is a single bond, O, or CR^cR^d;

each of R^a, R^b, R^c, and R^d is independently selected from H, and C_{1-4} alkyl; or

R^a and R^b together with the carbon to which they are attached may form a C_{3-7} cycloalkyl; or

R^c and R^d together with the carbon to which they are attached may form a C_{3-7} cycloalkyl;

Y is

- C_{1-4} alkyl optionally substituted with one or more groups independently selected from fluoro, OH, and phenyl (optionally substituted with one or more groups independently selected from C_{1-4} alkyl (optionally substituted with one or more halo), C_{1-4} alkoxy, halo and cyano), or
- C_{1-4} alkenyl comprising 1 double bond;

each of Cy_1 and Cy_2 is independently C_{6-10} aryl, or 5-10 membered heteroaryl;

each R^1 is independently selected from halo, C_{1-4} alkyl (optionally substituted with one or more halo), and C_{1-4} alkoxy (optionally substituted with one or more halo);

R^2 is:

- H,
- C_{1-4} alkyl optionally substituted with one or more independently selected R^{2a} groups,
- C_{3-7} cycloalkyl optionally substituted with one or more independently selected R^{2a} groups,

R^{2a} is

- halo,
- C_{1-6} alkoxy,
- OH,
- $C(=O)R^4$,
- $S(O)_2R^4$,
- CN,
- $NHC(=O)R^5$,
- $NHSO_2R^5$,
- 5-7 membered heterocycloalkyl (optionally substituted with one or more groups independently selected from C_{1-4} alkyl, and oxo), or

- 5-6 membered heteroaryl (optionally substituted with one or more groups independently selected from halo, OH, C_{1-4} alkoxy and C_{1-4} alkyl);

R^3 is selected from halo, C_{1-6} alkyl (optionally substituted with one or more halo), C_{1-6} alkoxy (optionally substituted with one or more halo, or phenyl), C_{1-6} thioalkoxy, phenyl (optionally substituted with one or more groups independently selected from halo, C_{1-4} alkyl (optionally substituted with one or more halo), C_{1-4} alkoxy, C(=O)-C_{1-4} alkoxy and CN);

R^4 is

- -OH,
- -C_{1-6} alkoxy,
- -*N*-linked 5-7 membered heterocycloalkyl (optionally substituted with one or more groups independently selected from C_{1-6} alkyl, and oxo),
- -$NR^{4a}R^{4b}$, or
- -$NHSO_2R^{4c}$;

Each of R^{4a} and R^{4b} is independently H, C_{1-4} alkyl (optionally substituted with phenyl (optionally substituted with one or more groups independently selected from halo, CN, C_{1-6} alkyl, and C_{1-6} alkoxy)), or C_{3-7} cycloalkyl;


R^{4c} is phenyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl (optionally substituted with one or more C_{1-4} alkyl) or C_{1-4} alkyl (optionally substituted with one or more halo);

R^5 is C_{1-4} alkyl (optionally substituted with one or more halo) or phenyl; and

the subscripts n and m are independently selected from 0, 1, and 2;

or a pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is according to Formula Ib:




Ib

,


wherein L_1, L_2, R^1, R^2, R^3, Cy^1, Cy^2, R^a, R^b, R^c, R^d, R^e, Y, n, and m are as described in claim 1.

3. A compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein Y is Me, Et, Pr, iPr, or –CH_2–Ph.

4. A compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein the compound is according to Formula IIIa or IIIb:



IIIa



IIIb

wherein R^2, L_2, Cy_2, R^3 and m are as described in claim 1.

5. A compound or pharmaceutically acceptable salt thereof according to claims 1-4, wherein R^2 is $-(CH_2)$-COOH, $-(CH_2)_3$-COOH, $-(CH_2)_3$-SO_2NH_2, or $-(CH_2)_3$-SO_2NHMe.

6. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein Cy_2 is phenyl, or naphthalene.

7. A compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-5, wherein Cy_2 is thiophenyl, benzothiophenyl, benzofuranyl, benzoisoxazolyl, benzoxazolyl or indolyl.

8. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-7, wherein m is 1 or 2.

9. A compound or pharmaceutically acceptable salt thereof according to claim 8, wherein each R^3 group is independently selected from F, Cl, Br, Me, CF_3, and OMe.

10. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-7, wherein m is 0.

11. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-10, wherein L_2 is a single bond.

12. A compound or pharmaceutically acceptable salt thereof according to any one of claims 1-10, wherein L_2 is $-CH_2$-.

13. A compound according to claim 1, wherein the compound is 4-[[(R)-1-(Benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-(3-chloro-benzyl)-amino]-butyric acid; or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof, according to any one of claims 1-13, and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition according to claim 14 comprising a further therapeutic agent.

16. A compound, or pharmaceutically acceptable salt thereof, according to any one of claims 1-13, or the pharmaceutical composition according to claim 14 or 15, for use as a medicament.

17. The compound, or pharmaceutically acceptable salt thereof, according to any one of claims 1-13, or the pharmaceutical composition according to claim 14 or 15, for use in the treatment or prophylaxis of inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.